The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating miRNA and extracellular vesicle containing miRNA as response biomarkers of anti PD-1/PD-L1 therapy in non-small-cell lung cancer.
 
Takehito Shukuya
Honoraria - Nichi-iko; Sanofi
 
Joseph Amann
Research Funding - Bristol-Myers Squibb
 
Vikas Ghai
No Relationships to Disclose
 
Kai Wang
No Relationships to Disclose
 
David Paul Carbone
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Abbvie; Abbvie; Adaptimmune; Adaptimmune; Adaptimmune; Adaptimmune; Adaptimmune; Adaptimmune; Agenus; Agenus; Agenus; Agenus; Agenus; Agenus; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; ARIAD; ARIAD; ARIAD; ARIAD; ARIAD; ARIAD; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Biocept; Biocept; Biocept; Biocept; Biocept; Biocept; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Celgene; Celgene; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Inovio Pharmaceuticals; Inovio Pharmaceuticals; Inovio Pharmaceuticals; Inovio Pharmaceuticals; Inovio Pharmaceuticals; Inovio Pharmaceuticals; Merck; Merck; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Novartis; Novartis; Palobiofarma; Palobiofarma; Palobiofarma; Palobiofarma; Palobiofarma; Palobiofarma; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; PrIME Oncology; PrIME Oncology; PrIME Oncology; PrIME Oncology; PrIME Oncology; PrIME Oncology; Stem CentRx; Stem CentRx; Stem CentRx; Stem CentRx; Stem CentRx; Stem CentRx; Takeda; Takeda; Takeda; Takeda; Takeda; Takeda
Research Funding - Bristol-Myers Squibb